Aethlon Medical Announces Pricing of $4.7 Million Public Offering

Core Viewpoint - Aethlon Medical, Inc. has announced a public offering of 8,100,000 shares of common stock and accompanying warrants, priced at $0.58 per share, aiming to raise approximately $4.7 million for general corporate purposes, including clinical trials and research and development [1][2]. Group 1: Offering Details - The public offering includes 8,100,000 shares of common stock and Class A and Class B warrants, all priced at $0.58 per share [1]. - Class A warrants will expire five years after issuance, while Class B warrants will expire one year after issuance [1]. - The offering is expected to close around May 17, 2024, pending customary closing conditions [1]. Group 2: Financial Proceeds - Gross proceeds from the offering are anticipated to be approximately $4.7 million before deducting fees and expenses [2]. - The net proceeds will be utilized for general corporate purposes, which may encompass clinical trial expenses, research and development, capital expenditures, and working capital [2]. Group 3: Company Overview - Aethlon Medical focuses on developing the Hemopurifier, an immunotherapeutic device aimed at treating cancer and life-threatening viral infections [5]. - The Hemopurifier has shown promise in removing life-threatening viruses and harmful exosomes in clinical and pre-clinical studies [5]. - The device has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses not addressed by approved therapies [5].